Phosphaturic mesenchymal tumors: what an endocrinologist should know
Tumor-induced osteomalacia (TIO), also known as “oncogenic osteomalacia”, is a rare cause of osteomalacia. TIO often has an insidious onset characterized clinically by progressive muscle weakness and bone pain with fractures. The hallmark biochemical finding is a persistent low serum phosphorus concentration due to renal phosphate wasting. The vast majority of cases of TIO result from production of the phosphaturic hormone fibroblast growth factor 23 (FGF23) by a histologically distinctive mesenchymal tumor, termed “phosphaturic mesenchymal tumor” (PMT). Circulating FGF23 induces internalization of renal sodium/phosphate co-transporters resulting in reduced proximal tubular phosphate reabsorption. FGF23 also inhibits production of 1α,25-dihydroxyvitamin D which is inappropriately low or normal in the context of hypophosphatemia. Diagnosis is often delayed owing to the rarity of the condition and an underappreciation for the role of phosphorus as a cause for the constellation of symptoms. Primary treatment for TIO is identification of the offending tumor and surgical removal. However, these tumors are notoriously difficult to find, precluding the opportunity for a curative surgery in many. In such cases, phosphate and calcitriol therapy is used to improve symptoms and heal the osteomalacia. Recently, molecular genetic studies have shown recurrent genetic events in PMT, including the novel fusions FN1–FGFR1 and less commonly FN1–FGF1. These fusion events are hypothesized to result in autocrine/paracrine signaling loops within the tumor, spurring tumorigenesis. This review will cover the clinical features, imaging characteristics, pathologic features, molecular genetic aspects, and therapy of PMT, with a brief discussion of other neoplasms that may cause TIO.
KeywordsTumor-induced osteomalacia Phosphaturic mesenchymal tumor Hyperphosphaturia Hypophosphatemia Rickets
This study received no grant from any funding agency in the public, commercial or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
Drs. Boland, Tebben, and Folpe declare that they have no conflicts of interest or relevant financial relationships.
This manuscript is a review of the literature and does not contain original research either on animal or on human subjects.
For this type of study, formal consent is not required.
- 2.Prader A, Illig R, Uehlinger RE, Stalder G (1959) Rachitis infolge knochentumors (rickets caused by bone tumors). Helv Pediatr Acta 14:554–565Google Scholar
- 7.Fletcher CDM (2013) WHO classification of tumours of soft tissue and bone. IARC Press, LyonGoogle Scholar
- 8.Agaimy A, Michal M, Chiosea S, Petersson F, Hadravsky L, Kristiansen G et al (2017) Phosphaturic mesenchymal tumors: clinicopathologic, immunohistochemical and molecular analysis of 22 cases expanding their morphologic and immunophenotypic spectrum. Am J Surg Pathol 41(10):1371–1380CrossRefPubMedGoogle Scholar
- 19.Krebs EG, Stull JT (1975) Protein phosphorylation and metabolic control. Ciba Found Symp 31:355–367Google Scholar
- 21.Neuman WF (1980) Bone material and calcification mechanisms. In: Urist MR (ed) Fundamental and clinical bone physiology. Lippincott, Philadelphia, pp 83–107Google Scholar
- 27.Berndt TJ, Knox FG (1992) Renal regulation of phosphate excretion. In: Seldin DW, Giebisch GH (eds) The kidney: physiology and pathophysiology, 2nd edn. Raven Press, New York, pp 2511–2532Google Scholar
- 28.Knox FG, Haramati A (1985) Renal regulation of phosphate excretion. In: Seldin DW, Giebisch GH (eds) The kidney: physiology and pathophysiology. Raven Press, New York, pp 1351–1396Google Scholar
- 32.Taketani Y, Segawa H, Chikamori M, Morita K, Tanaka K, Kido S et al (1998) Regulation of type II renal Na+-dependent inorganic phosphate transporters by 1,25-dihydroxyvitamin D3. Identification of a vitamin D-responsive element in the human NAPi-3 gene. J Biol Chem 273(23):14575–14581CrossRefPubMedGoogle Scholar
- 47.Kawai S, Ariyasu H, Furukawa Y, Yamamoto R, Uraki S, Takeshima K et al (2017) Effective localization in tumor-induced osteomalacia using (68)Ga-DOTATOC-PET/CT, venous sampling and 3T-MRI. Endocrinol Diabetes Metab Case Rep 2017. https://doi.org/10.1530/EDM-17-0005
- 49.Singh D, Chopra A, Ravina M, Kongara S, Bhatia E, Kumar N et al (1072) Oncogenic osteomalacia: role of Ga-68 DOTANOC PET/CT scan in identifying the culprit lesion and its management. Br J Radiol 2017(90):20160811Google Scholar
- 68.White KE, Larsson TE, Econs MJ (2006) The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev 27(3):221–241CrossRefPubMedGoogle Scholar
- 84.Jan de Beur S, Miller PD, Weber TJ, Peacock M, Ruppe MD, Insogna K, Luca D, Theodore-Oklota C, Martin JS, Carpenter T (2017) Effects of burosumab (KRN23), a human monoclonal antibody to FGF23, in patients with tumor-induced osteomalacia (TIO) or epidermal nevus syndrome (ENS). ASBMR Poster SU0325Google Scholar
- 86.Collins MT (2015) Strking response of tumor-induced osteomalacia to the FGFR inhibitor NVP-BGJ398. In: Annual Meeting of the American Society of Bone and Mineral Research SA0035Google Scholar